Slingshot members are tracking this event:
Target enrollment of 500 patients in AR101 PALISADE Phase 2 studies is on track to complete in the second half of this year, and we expect top-line data in the second half of 2017
Slingshot Insights Explained
May 16, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Palisade, Peanut-allergic Individuals